DESTINY PHARMA LIMITED
DESTINY PHARMA LIMITED is a private limited company registered in England and Wales under company number 03167025. It was incorporated on 4 March 1996, initially as DESTINY CONSULTANTS LIMITED, and traded under several later names, including DESTINY PHARMA LIMITED (1997–2017), DESTINY PHARMA HOLDINGS LIMITED (2017) and DESTINY PHARMA PLC (22 August 2017 to 3 September 2024), before reverting to its current name on 3 September 2024. Companies House records the company’s current status as liquidation: it entered administration on 21 August 2024 and moved into creditors’ voluntary liquidation on 1 August 2025, with joint liquidators from Cork Gully LLP. Its registered office is C/O Cork Gully LLP, 40 Villiers Street, London, WC2N 6NJ, and Companies House classifies its principal activity under SIC code 72190, other research and experimental development on natural sciences and engineering.
Before entering administration, DESTINY PHARMA LIMITED operated as DESTINY PHARMA PLC, a clinical-stage biotechnology company based in Brighton developing novel antimicrobial medicines intended to prevent life-threatening bacterial infections, including those caused by antimicrobial-resistant organisms. Its lead programme, the XF platform, centred on XF-73, a candidate nasal gel designed to prevent post-surgical bacterial infections. DESTINY PHARMA PLC’s shares had been admitted to trading on AIM, the London Stock Exchange’s market for smaller growing companies, under the ticker DEST, until shareholders approved cancellation of that admission at a general meeting on 13 August 2024, after which the company converted to private limited company status.
DESTINY PHARMA LIMITED entered administration on 21 August 2024, less than two weeks after its AIM delisting took effect, having been unable to secure a licensing partner or sufficient funding to progress XF-73 Nasal through further clinical trials. During the administration, the joint administrators sold the company’s XF drug-development assets, including the XF-73 intellectual property and associated regulatory designations, to Moirai Acquisitions Limited, a subsidiary of EMV Capital plc, for consideration of up to £2.475 million; Moirai Acquisitions was subsequently renamed AMR Bio and continues to develop those assets as a separate legal entity with no verified ownership link to DESTINY PHARMA LIMITED. DESTINY PHARMA LIMITED itself moved from administration into creditors’ voluntary liquidation on 1 August 2025 and, based on the information reviewed for this profile, remains in that process. Its last filed accounts were made up to 31 December 2023, and its confirmation statement, last dated 8 December 2023, is recorded as overdue.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of DESTINY PHARMA LIMITED
Companies House’s persons-with-significant-control (PSC) register for DESTINY PHARMA LIMITED contains an active statement, filed 4 March 2017, that the company “knows or has reasonable cause to believe that there is no registrable person or registrable relevant legal entity in relation to the company,” meaning no individual or entity currently meets the UK’s PSC disclosure threshold. Companies House does not separately publish a full register of ordinary shareholders outside the confirmation statement mechanism; DESTINY PHARMA LIMITED’s last confirmation statement is dated 8 December 2023, when it still traded as DESTINY PHARMA PLC with shares admitted to trading on AIM, and its next statement, due by 22 December 2024, is recorded as overdue. Because the company was AIM-listed for most of the period covered by its most recent filings, its shareholder base at that time would have included a broad mix of institutional and retail investors typical of a quoted company, rather than a small number of named holders; no reliable primary source verified for this profile lists those individual AIM-era shareholdings or percentages.
Data availability
Shareholder disclosure for DESTINY PHARMA LIMITED is classified as Restricted / Historical: the only verifiable current record is the PSC statement of no registrable control, and the most recent confirmation statement predates the company’s 2024 conversion from a public to a private company and is now overdue, so an up-to-date, itemised shareholder list could not be independently verified for this profile.
Sources
Companies House, DESTINY PHARMA LIMITED persons with significant control, https://find-and-update.company-information.service.gov.uk/company/03167025/persons-with-significant-control, notification dated 4 March 2017, retrieved 18 September 2026.
Companies House, DESTINY PHARMA LIMITED overview and confirmation statement filing, https://find-and-update.company-information.service.gov.uk/company/03167025, retrieved 18 September 2026.
Officers
16
Directors and officers of DESTINY PHARMA LIMITED
Companies House records six active directors of DESTINY PHARMA LIMITED as of 18 September 2026: Debra Stephanie Barker (appointed 1 January 2020), Nigel Stanley Brooksby (appointed 1 June 2022), Dr William Guy Love (appointed 17 June 1996), James Patrick Stearns (appointed 1 June 2022), Christopher John Tovey (appointed 1 September 2023) and Aled Paton Williams (appointed 1 June 2022). Barker is recorded with Swiss nationality and residence in Switzerland; Williams is recorded with British nationality and residence in Switzerland; Brooksby, Love, Stearns and Tovey are recorded as British nationals resident in the United Kingdom. No company secretary is currently in post. Companies House additionally records around twenty former officer appointments dating back to the company’s 1996 incorporation, reflecting its history as an AIM-listed public company before its September 2024 conversion to a private company. Because DESTINY PHARMA LIMITED entered administration on 21 August 2024 and moved into creditors’ voluntary liquidation on 1 August 2025, day-to-day management authority in practice rests with the appointed insolvency practitioners for matters concerning the liquidation, even though Companies House continues to list these six individuals as active directors.
Data availability
Officer information for DESTINY PHARMA LIMITED is classified as Full for currently active directors: UK Companies House disclosure rules publish appointment dates, nationality and country of residence for each director, though not full dates of birth or residential addresses. Nationality shown here is as officially disclosed and has not been inferred from any director’s name, residence or correspondence address.
Sources
Companies House, DESTINY PHARMA LIMITED officers, https://find-and-update.company-information.service.gov.uk/company/03167025/officers, retrieved 18 September 2026.
Registry feed — rows exactly as filed with Companies House, including entries the profile above does not cover.
Group Structure
Group structure of DESTINY PHARMA LIMITED
DESTINY PHARMA LIMITED’s own PSC register shows no controlling parent; a formal statement that no registrable person or entity of significant control exists was filed 4 March 2017. Companies House’s PSC register for DESTINY PHARMA (BRIGHTON) LIMITED (company number 10517676) names Destiny Pharma Plc (03167025), i.e. this company under its former name, as holding 75% or more of that company’s shares and voting rights and the right to appoint or remove its directors, notified 8 December 2016, confirming DESTINY PHARMA (BRIGHTON) LIMITED as a verified direct subsidiary. DESTINY PHARMA (BRIGHTON) LIMITED was a dormant company registered at the Sussex Innovation Centre, Falmer, Brighton, and was dissolved on 24 June 2025. No other verified subsidiaries or sister companies were identified. This reflects Companies House data reviewed 18 September 2026.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| DESTINY PHARMA (BRIGHTON) LIMITED | United Kingdom | 10517676 | Direct subsidiary | 75% or more of shares and voting rights | Dissolved 24 June 2025 | Notified 8 December 2016 |
Recent structural changes
During DESTINY PHARMA LIMITED’s administration, the joint administrators sold the company’s XF drug-development assets, including the XF-73 intellectual property and associated regulatory designations, to Moirai Acquisitions Limited, a subsidiary of EMV Capital plc, for consideration of up to £2.475 million; this was a sale of specific business assets rather than a change in DESTINY PHARMA LIMITED’s own shareholding, and Moirai Acquisitions, since renamed AMR Bio, is a separate legal entity with no verified corporate ownership link to DESTINY PHARMA LIMITED. DESTINY PHARMA (BRIGHTON) LIMITED, the company’s dormant subsidiary, was dissolved on 24 June 2025. DESTINY PHARMA LIMITED itself moved from administration into creditors’ voluntary liquidation on 1 August 2025.
Data availability
Corporate-linkage information for DESTINY PHARMA LIMITED is classified as Subsidiaries only / Historical: no parent company is registered, one direct subsidiary is verified via the PSC register, but that subsidiary is now dissolved and the group’s principal trading assets have since been sold out of the corporate structure entirely as part of the liquidation.
Sources
Companies House, DESTINY PHARMA (BRIGHTON) LIMITED persons with significant control, https://find-and-update.company-information.service.gov.uk/company/10517676/persons-with-significant-control, notified 8 December 2016, retrieved 18 September 2026.
Proactive Investors, “EMV Capital snaps up antibiotic assets from collapsed Destiny Pharma,” https://www.proactiveinvestors.com/companies/news/1078864/emv-capital-snaps-up-antibiotic-assets-from-collapsed-destiny-pharma-1078864.html, retrieved 18 September 2026.
DESTINY PHARMA LIMITED
United Kingdom
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does DESTINY PHARMA LIMITED do?
DESTINY PHARMA LIMITED (company number 03167025) is a private limited company registered in England and Wales, incorporated 4 March 1996 and registered at C/O Cork Gully LLP, 40 Villiers Street, London, WC2N 6NJ; Companies House classifies it under SIC code 72190, research and experimental development on natural sciences and engineering. Formerly Destiny Pharma PLC, it operated as a clinical-stage biotechnology company developing antimicrobial medicines, notably the XF-73 candidate, before entering administration on 21 August 2024.
Who owns DESTINY PHARMA LIMITED?
Companies House records no registrable person or entity of significant control for DESTINY PHARMA LIMITED (statement filed 4 March 2017); a full, current itemised shareholder register was not independently verified, and the company's last confirmation statement (8 December 2023) is overdue.
Who is DESTINY PHARMA LIMITED's UBO (Ultimate Beneficial Owner)?
No Ultimate Beneficial Owner (UBO) data is recorded for DESTINY PHARMA LIMITED; access to beneficial-ownership data in this jurisdiction is governed by its own register rules.
What is DESTINY PHARMA LIMITED's company registration number?
DESTINY PHARMA LIMITED's registration number is 03167025, filed with Companies House in United Kingdom. Its current status on the register is intermediate.
Is DESTINY PHARMA LIMITED still an active company?
DESTINY PHARMA LIMITED's status on Companies House is listed as intermediate, not currently active.
When was DESTINY PHARMA LIMITED incorporated?
DESTINY PHARMA LIMITED was incorporated on 4 March 1996, according to Companies House.
What is DESTINY PHARMA LIMITED's registered address?
The registered address on file for DESTINY PHARMA LIMITED is London, United Kingdom.
What legal structure is DESTINY PHARMA LIMITED registered as?
DESTINY PHARMA LIMITED is registered as a Private limited company (Ltd.) in United Kingdom.
Is DESTINY PHARMA LIMITED listed on a stock exchange?
DESTINY PHARMA LIMITED's shares were formerly admitted to trading on AIM (London Stock Exchange) under ticker DEST; shareholders approved cancellation of that admission on 13 August 2024, and the company converted from a PLC to a private limited company on 3 September 2024. It is not currently listed on any stock exchange.
Who are the officers/directors of DESTINY PHARMA LIMITED?
Companies House lists six active directors of DESTINY PHARMA LIMITED as of 18 September 2026: Debra Barker, Nigel Brooksby, Dr William Love, James Stearns, Christopher Tovey and Aled Williams; no company secretary is currently in post.
Does DESTINY PHARMA LIMITED have a parent company or subsidiaries?
DESTINY PHARMA LIMITED has no registered parent company. Its dormant subsidiary, DESTINY PHARMA (BRIGHTON) LIMITED (75% or more ownership, notified 8 December 2016), was dissolved on 24 June 2025. The company's XF-73 drug assets were sold to Moirai Acquisitions Limited (EMV Capital plc), later renamed AMR Bio, during administration in 2025.
Can Zavia monitor changes to DESTINY PHARMA LIMITED's ownership over time?
This profile reflects a point-in-time snapshot from Companies House. Zavia's monitoring API can track changes to DESTINY PHARMA LIMITED's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access DESTINY PHARMA LIMITED's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United Kingdom, so records like DESTINY PHARMA LIMITED's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Companies House and was last synced on 18 September 2026.